Emerging Risk of Campylobacter spp. Infection Associated With Anti-BCMA and Anti-GPRC5D Bispecific Antibodies

1

Bispecific antibodies targeting BCMA and GPRC5D show efficacy in refractory multiple myeloma but increase infection risk.
2

In a cohort of 85 patients, 9 individuals experienced Campylobacter infections, including bloodstream and gastrointestinal cases.
3

Hypogammaglobulinemia, a side effect of BCMA-targeted therapies, predisposes patients to infections like Campylobacter spp.
4

The study highlights the need for targeted preventive strategies and surveillance for infections in immunocompromised patients.
5

Robust quantitative data on Campylobacter infection rates in multiple myeloma patients receiving bispecific antibodies are lacking.

Open Forum Infectious Diseases

by Idoia Bilbao, María Ansón, Sara Villar, Iñigo Pineda, Laura Gárriz, Manuel Pina-Sánchez, Luis-Esteban Tamariz-Amador, Paula Rodríguez-Otero, José Ramón Yuste, José L del Pozo
November 4, 2025

1